Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis

被引：2
作者：
Wei, Chenyu [1 ]
Du, Xuelin [2 ]
Hu, Jiexuan [1 ]
Dong, Yin [1 ]
Chen, Yan [3 ]
Cao, Bangwei [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Clin Trial Inst, Beijing 100050, Peoples R China
[3] Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 198卷
基金：
中国国家自然科学基金;
关键词：
Gastric cancer; Perioperative chemotherapy; Neoadjuvant chemotherapy; Meta; -analysis; MULTICENTER PHASE-III; NEOADJUVANT CHEMOTHERAPY; D2; GASTRECTOMY; OPEN-LABEL; CAPECITABINE; OXALIPLATIN; CISPLATIN; ADENOCARCINOMA; DOCETAXEL; SURGERY;
D O I：
10.1016/j.critrevonc.2023.104082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: The study aimed to investigate the prognosis and safety of perioperative chemotherapy (PC) compared with adjuvant chemotherapy (AC). Methods: We systematically searched and assessed studies in PubMed, Embase, and the Cochrane Library from inception to 1st September 2022. Results: Eighteen studies were eligible for the analysis, including 4686 patients in total. Our study found that patients with resectable gastric cancer undergoing PC had favorable prognosis on OS (HR 0.77; 95% CI 0.69 -0.87) and DFS (HR 0.76; 95% CI 0.69 -0.84) than those who undergoing AC. Addition of neoadjuvant chemotherapy (NAC) to AC provided higher R0 resection rate but did not increase the risk of postoperative complication rate and most of the adverse event rates. Conclusion: Our study demonstrated that PC shows better OS and DFS in Asians with resectable gastric cancer compared with AC. PC should be preferred because of its favorable prognosis and similar safety.
引用
收藏
页数：10
相关论文
共 44 条
[41]   Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J].
Zhang, Xiaotian ;
Liang, Han ;
Li, Ziyu ;
Xue, Yingwei ;
Wang, Yanong ;
Zhou, Zhiwei ;
Yu, Jiren ;
Bu, Zhaode ;
Chen, Lin ;
Du, Yian ;
Wang, Xinbao ;
Wu, Aiwen ;
Li, Guoli ;
Su, Xiangqian ;
Xiao, Gang ;
Cui, Ming ;
Wu, Dan ;
Chen, Li ;
Wu, Xiaojiang ;
Zhou, Yanbing ;
Zhang, Lianhai ;
Dang, Chengxue ;
He, Yulong ;
Zhang, Zhongtao ;
Sun, Yihong ;
Li, Yong ;
Chen, Huanqiu ;
Bai, Yuxian ;
Qi, Changsong ;
Yu, Peiwu ;
Zhu, Guanbao ;
Suo, Jian ;
Jia, Baoqing ;
Li, Leping ;
Huang, Changming ;
Li, Fei ;
Ye, Yingjiang ;
Xu, Huimian ;
Wang, Xin ;
Yuan, Yannan ;
Jian-Yu, E. ;
Ying, Xiangji ;
Yao, Chen ;
Shen, Lin ;
Ji, Jiafu .
LANCET ONCOLOGY, 2021, 22 (08) :1081-1092
[42]   Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis [J].
Zhao, Jun-hua ;
Gao, Peng ;
Song, Yong-xi ;
Sun, Jing-xu ;
Chen, Xiao-wan ;
Ma, Bin ;
Yang, Yu-chong ;
Wang, Zhen-ning .
BMC CANCER, 2016, 16
[43]   The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial [J].
Zhao, Qun ;
Lian, Changhong ;
Huo, Zhibin ;
Li, Ming ;
Liu, Yang ;
Fan, Liqiao ;
Tan, Bibo ;
Zhao, Xuefeng ;
Zhang, Zhidong ;
Wang, Dong ;
Liu, Yu ;
Guo, Honghai ;
Yang, Peigang ;
Tian, Yuan ;
Li, Yong .
CANCER MEDICINE, 2020, 9 (16) :5731-5745
[44]   The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy [J].
Zhou, Kai ;
Wang, Anqiang ;
Wei, Jingtao ;
Ji, Ke ;
Li, Zhongwu ;
Ji, Xin ;
Fu, Tao ;
Jia, Ziyu ;
Wu, Xiaojiang ;
Zhang, Ji ;
Bu, Zhaode .
FRONTIERS IN ONCOLOGY, 2022, 11
12345